Alert detail
FDA Approval: WELTRUZA (OLANZAPINE) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-NDA219007Specialty: NeurologyAdded: 10/14/2026Effective: October 8, 2026federal register
What changed
New olanzapine ER injectable from Teva; verify Part D billing before submitting.
Who’s affected: Neurology billing teams · Effective: October 8, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.